Dual Therapy with ACE Inhibitors and Angiotensin II Receptor Blockers in Proteinuric IgA Nephropathy Patients  by Chow, Kai-Ming et al.
Brief Communication
Hong Kong J Nephrol • October 2007 • Vol 9 • No 2 89
INTRODUCTION
The weight of experimental evidence supports dual
pharmacologic blockade of the renin–angiotensin
system with angiotensin-converting enzyme (ACE)
inhibitors and angiotensin II receptor blockers in
proteinuric renal disease [1,2]. Nonetheless, exag-
gerated therapeutic benefits are frequently the rule
rather than the exception in the experimental or trial
setting. As compared to the realistic clinical situation,
the carefully controlled setting of well-funded trials
reveal how treatments work under ideal instead of
customary conditions. The difference between the
clinical trial setting (efficacy) and actual practice
(effectiveness) should be borne in mind before rec-
ommendation of any new therapy as the standard of
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care. With this in mind, we examine the effectiveness
and safety of dual therapy on a cohort of adults with
proteinuric IgA nephropathy in usual clinical setting.
The primary end point was the reduction in proteinuria,
which has been shown to be a significant risk factor for
end-stage renal disease [3].
METHODS
In a single-center observational uncontrolled study,
we recruited patients with biopsy-proven IgA ne-
phropathy who demonstrated persistent proteinuria
exceeding 1 g daily despite monotherapy with either
ACE inhibitors or angiotensin II receptor blockers
(using maintenance defined daily dose of at least 1.0)
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for a minimum of 3 months. All subjects had clinically
significant proteinuria over 1 g daily on two or more
consecutive measurements 8 weeks apart. As such,
exclusion criteria were kept to a minimum. After the
baseline evaluation, patients were administered dual
therapy with ACE inhibitors and angiotensin II receptor
blockers, the choice and dose of which were at the
discretion of nephrologists. Titration schedule was not
mandated. The pragmatic nature of this study allowed
the choice of medications to be decided by the phy-
sician, in keeping with real life and generalizabil-
ity. None of them were administered steroids,
cyclophosphamide or azathioprine.
Chronicity-based histologic grading of IgA ne-
phropathy was defined on the extent of glomerular
sclerosis (glomerular grading), the degree of tubular
loss or interstitial fibrosis (tubulointerstitial grading),
and the evaluation of hyaline arteriolosclerosis [4–6].
Patients were monitored at every 3-monthly out-
patient clinic visit. In terms of treatment outcomes,
we measured the average blood pressure, serum
potassium, creatinine and daily protein excretion.
Treatment response was evaluated within 6 months of
dual therapy, because the maximum antiproteinuric
effect by virtue of the renin–angiotensin system
blockade is in general observed soon after starting
treatment, usually within 6 months [7]. Blood pressure
parameters in our study were quantified as the time-
averaged readings over a period of 6 months before
and after dual therapy. Glomerular filtration rate
was estimated by the abbreviated version of the
Modification of Diet in Renal Disease (MDRD) Study
equation, which has been modified and validated in
Chinese patients with chronic kidney disease [8]. Dose
titration of medication was allowed to target blood
pressure control, taking into account the control of
proteinuria and adverse effects including hyperkalemia.
Because prescription of different ACE inhibitors and
angiotensin II receptor blockers were allowed, we
calculated the defined daily dose (DDD) in order to
compare doses of different drugs within a class [9].
RESULTS
Between April 2005 and January 2007, 12 patients
(mean age, 40.9 ± 6.5 years; 6 men and 6 women) in
the outpatient renal department received dual ACE
inhibitors and angiotensin II receptor blockers for IgA
nephropathy when proteinuria exceeded 1 g daily
during monotherapy. No patient was lost to follow-up.
Table 1 summarizes their clinical and demographic
characteristics. In particular, over half of them (7
patients) had at least stage 3 chronic kidney disease
with estimated glomerular filtration rate < 60 mL/min/
1.73 m2. The median duration of IgA nephropathy was
8.5 years (mean, 7.7 ± 5.9 years) since biopsy diagnosis.
Mean proteinuria values at baseline were 2.84 ± 1.32 g
daily (median, 2.35; interquartile range, 1.63–4.28 g
daily). Optimal blood pressure control was achieved
during monotherapy; the average systolic blood pres-
sure and mean arterial pressure were 118.1 ± 15.0
mmHg and 89.7 ± 13.3 mmHg, respectively, at baseline.
The majority of the patients in this study (11 pa-
tients) received ACE inhibitors first, followed by addi-
tion of angiotensin II receptor blockers. At baseline,
the median DDD of ACE inhibitors received by patients
was 2.0 (range, 1.0–5.0). None of the patients received
concomitant spironolactone or aldosterone antagonists
during the observation period. After dual therapy, the
dose of ACE inhibitors was reduced in general, with a
median DDD of 1.0 (range, 0.5–2.0). Median DDD of
angiotensin II receptor blockers during dual therapy
was 1.0 (range, 0.5–1.0). The two most commonly
prescribed angiotensin II receptor blockers in the cohort
were telmisartan and valsartan.
Table 2 shows the detailed data before and after dual
therapy. Proteinuria decreased in nine (75%) subjects
after dual therapy. The median percentage reduction in
proteinuria was 32.6% (median reduction, 900 mg
daily) decline over baseline. Despite a similar degree
Table 1. Baseline characteristics of the study cohort*
Demographics
Age (yr) 40.9 ± 6.5 (30–50)
Gender (male/female) 6/6
Weight (kg) 61.4 ± 11.9
BMI (kg/m2) 23.0 ± 3.7
Hypertension
Systolic BP (mmHg) 118.1 ± 15.0
Diastolic BP (mmHg) 75.4 ± 13.0
Number of antihypertensive drugs given 1.5 [1, 2.75]
Renal function and biochemistry
Serum creatinine (µmol/L)† 130.5 ± 63.0
Estimated GFR (mL/min/1.73 m2)‡§ 59.8 ± 22.9
Urinary protein excretion (g/d) 2.35 [1.63, 4.28]
Serum potassium (mmol/L) 4.15 ± 0.35
Renal biopsy and histologic finding
Median duration of diagnosis (yr) 8.5
Glomerular grade (1/2/3) 8/4/0
Tubulointerstitial grade (1/2/3) 7/5/0
Presence of hyaline arteriolosclerosis (%) 25
*Data are presented as mean ± standard deviation (range) or
median [interquartile range] unless otherwise stated; †to convert
serum creatinine in µmol/L to mg/dL, divide by 88.4; ‡to convert
GFR in mL/min to mL/s, multiply by 0.01667; §estimated GFR was
assessed by the modified MDRD equations based on and validated
in Chinese patients with chronic kidney disease [8]. BMI = body
mass index; BP = blood pressure; GFR = glomerular filtration rate.
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of blood pressure control, dual therapy with ACE
inhibitors and angiotensin II receptor blockers resulted
in a significant decrease in proteinuria (Figure) from a
median value of 2.35 g daily (interquartile range,
1.63–4.28) at baseline to 1.65 g daily (interquartile
range, 0.76–2.17) (p = 0.023). In addition, there were
no correlations between proteinuria reduction and
changes in mean arterial pressure after dual therapy.
Two patients developed transient hyperkalemia after
dual therapy, which normalized by dietary advice and/
or adding diuretic (without discontinuation of dual
therapy). In general, no significant increase in serum
potassium concentration (4.29 ± 0.37 compared with
4.15 ± 0.35 mmol/L at baseline, p = 0.11) occurred.
None of our patients experienced symptomatic postural
hypotension, angioedema or acute renal failure. A rising
trend of serum creatinine was detected before and after
dual therapy, with an increase in the mean value over
6 months from 130.5 ± 63.0 to 143.7 ± 56.9 µmol/L
(p = 0.002). No conclusion can be made regarding the
long-term renoprotective effect owing to the short-term
follow-up; it cannot be readily ascertained by measuring
serum creatinine concentrations over a period of only
6 months before and after dual therapy.
DISCUSSION
Our results confirm the reproducible antiproteinuric
benefit of dual therapy with ACE inhibitors and
angiotensin II receptor blockers among patients with
proteinuric IgA nephropathy in a routine clinical set-
ting. Another notable finding of the study was that
the significant reduction of proteinuria seems to be
independent of blood pressure reduction. Compared to
the standalone strategy using either ACE inhibitors or
angiotensin II receptor blockers, the effect of dual
Table 2. Detailed laboratory and clinical data before and after dual therapy with ACE inhibitors and angiotensin II receptor blockers*
Parameter Before dual therapy After dual therapy p
Treatment
Lisinopril, 2.5/5/10/20 mg/d 0/0/4/3 1/1/3/2
Ramipril, 2.5/5/10 mg/d 1/2/1 2/2/0
Perindopril, 2 mg/d 0 1 Not
Valsartan, 80 mg/d 1 5 applicable
Telmisartan, 20/40 mg/d 0 4/2
Losartan, 25 mg/d 0 1
Proteinuria (g/d) 2.35 [1.63, 4.28] 1.65 [0.76, 2.17] 0.023†
Serum potassium (mmol/L) 4.15 ± 0.35 4.29 ± 0.37 0.11
Serum creatinine (µmol/L)‡ 130.5 ± 63.0 143.7 ± 56.9 0.002
Estimated GFR (mL/min/1.73 m2)§ || 59.8 ± 22.9 50.3 ± 16.8 0.007
Mean arterial pressure (mmHg) 89.7 ± 13.3 87.0 ± 13.1 0.23
*Data are presented as mean ± standard deviation (range) or median [interquartile range] unless otherwise stated; †comparison with baseline
using Wilcoxon signed rank test; ‡to convert serum creatinine in µmol/L to mg/dL, divide by 88.4; §to convert GFR in mL/min to mL/s,
multiply by 0.01667; ||estimated GFR was assessed by the modified MDRD equations based on and validated in Chinese patients with




















Figure. Effects of dual therapy with ACE inhibitors and angiotensin
II receptor blockers on proteinuria.
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therapy in our study was a 32.6% reduction in pro-
teinuria. This is quantitatively comparable to those
seen in other randomized trials of dual therapy for
nondiabetic proteinuric kidney disease, in which
lowering in proteinuria between 10% and 40% have
been reported [10–12].
The mechanisms that underlie the observed bene-
fit could relate to additive advantage of blocking
angiotensin II production completely in addition to
increasing bradykinin levels [1]. In particular, recent
evidence suggests that ACE inhibitors may not
completely block the formation of angiotensin II due
to upregulation of non-ACE-dependent pathways, a
phenomenon known as ACE escape [1,13]. How about
additional mechanisms specific to IgA nephropathy?
Recent publications emphasize the putative role of
angiotensin II receptor blockers in modifying pore size
distribution by reducing the radius of large unselective
pores, thus resulting in less leakage of protein into the
urine [14]. Another proposed mechanism by which dual
therapy exerts a benefit in IgA nephropathy involves
the reduction in urinary transforming growth factor-`
levels [15,16]. Apart from our recent double-blind
randomized placebo-controlled study showing the
superior antiproteinuric effect of angiotensin II receptor
blockers in IgA nephropathy [17], accumulating data
support the effect of dual therapy in IgA nephropathy.
Buttressing the literature are several clinical trials that
reaffirmed the antiproteinuric benefit of dual therapy
exclusively in IgA nephropathy subjects, including
pediatric [18] and adult patients [19,20]. Notably, the
additive antiproteinuric effect after combining ACE
inhibitors and angiotensin II receptor blockers in 43
normotensive patients with IgA nephropathy was
confirmed regardless of aldosterone breakthrough [19],
as measured by the plasma aldosterone rise during
treatment.
Taken together, systematic reviews and meta-
analyses of randomized controlled trials have provided
ample evidence that combining an ACE inhibitor with
an angiotensin II receptor blocker provides an addition-
al decrease in proteinuria over monotherapy in
nondiabetic kidney disease [2]. These findings are
bolstered by the consistency or reproducibility as dem-
onstrated in our study, whose setting resembles the real
world situation where patients usually come under
medical attention after proteinuria has been present for
some time already, when treatment was started at a
relatively late stage of chronic kidney disease. In fact,
the most striking difference between our study and
previous controlled trials was our reporting the anti-
proteinuric effect in an everyday clinical setting. In
particular, no significant rise in serum potassium level,
a major concern with dual therapy, was observed even
in situations outside the judiciously controlled setting,
although our sample size was small.
Our findings have several implications for ongoing
clinical research. There remains a paucity of evidence
regarding the optimum dose of ACE inhibitors and
angiotensin II receptor blockers. It is anticipated that
the growing application of dual therapy for blockade
of the renin–angiotensin system and dose-escalation
studies will help to determine the best strategy of drug
dose. Likewise, the growing interest in aldosterone
blockade, by spironolactone for instance, holds promise
for more effective proteinuria reduction [21].
On the other hand, our observational study has several
limitations, related both to being an observational study
in general and to this study in particular. Observational
studies are never a substitute for a properly performed,
adequately powered randomized controlled trial.
However, this study provides information on therapeutic
benefits in real clinical practice. The second limitation
of our study is the uncontrolled and non-blinded design,
without a comparison group. We cannot overrule the
possibility that the superior antiproteinuric effect
achieved by dual therapy may well be obtained by simply
increasing the dose of monotherapy, for instance, with
ACE inhibitor. Furthermore, a question of interest is
whether the additive antiproteinuric effect of dual therapy
is sustained over time. However, it is noteworthy that
IgA nephropathy constituted 50% of primary diagnosis
among recruited subjects from the COOPERATE trial
(combination treatment of angiotensin II receptor blocker
and ACE inhibitor in nondiabetic renal disease) [22],
which is thus far the largest of parallel-group studies with
the highest quality and longest treatment duration
(3 years) [2] to demonstrate the therapeutic benefit of
dual therapy. In addition, according to another long-term
parallel-group study, in which 52% of patients had IgA
nephropathy, treatment benefit of proteinuria reduction
after dual therapy was sustained for 3 years, accompanied
by slowing of renal function deterioration [23]. A fourth
limitation was that we did not measure plasma renin
activities and plasma aldosterone levels, and cannot
dissect the effect of dual therapy on the degree of renin–
angiotensin system blockade. Also, we are underpowered
to discern the differences between the responders and
nonresponders to dual therapy.
Finally, a cautionary note should be made for the
putative benefit ascribed to proteinuria reduction as
surrogate outcomes [24]. This is based on the premise
that amelioration of the progression of renal disease is
accompanied by a decrease in proteinuria. There is
mounting evidence to suggest that, in addition to blood
pressure control, proteinuria should be considered as
an independent risk factor and an important treatment
target for renal protection [25]. Reduction of proteinuria
with renin–angiotensin system blockade results in
salutary protection against protein-induced renal
fibrosis, which should theoretically translate into
preservation of renal function in the long run [1,26].
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Although proteinuria has been shown to correlate with
renal outcome, a more definitive evaluation of dual
therapy should preferably be based on hard clinical end
points (such as doubling of serum creatinine levels and
development of end-stage renal disease).
In conclusion, we analyzed anecdotal observation-
al data on dual therapy with ACE inhibitors and
angiotensin II receptor blockers among IgA ne-
phropathy patients with proteinuria exceeding 1 g daily
despite monotherapy, to determine the therapeutic
effects in usual clinical practice. Our analysis showed
that dual therapy is effective in the reduction of
proteinuria, independent of blood pressure lowering
effect, compared with monotherapy.
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